Cardinal Health (CAH) 10-Q 6 Feb 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Dec. 31, 2013	Jan. 31, 2014
Document and Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Dec-13	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Trading Symbol	'cah	'
Entity Registrant Name	'CARDINAL HEALTH INC	'
Entity Central Index Key	'0000721371	'
Current Fiscal Year End Date	'--06-30	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	342,888,531

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Earnings (USD $)	3 Months Ended		6 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Income Statement [Abstract]	'	'	'	'
Revenue	$22,240	$25,232	$46,763	$51,121
Cost of products sold	20,895	24,008	44,155	48,739
Gross margin	1,345	1,224	2,608	2,382
Operating expenses:	'	'	'	'
Distribution, selling, general and administrative expenses	766	699	1,497	1,388
Restructuring and employee severance	10	1	20	6
Amortization and other acquisition-related costs	56	25	105	53
Impairments and loss on disposal of assets	9	5	9	6
Litigation (recoveries)/charges, net	-15	-12	-13	-34
Operating earnings	519	506	990	963
Other income, net	-6	-4	-10	-12
Interest expense, net	33	27	66	53
Earnings before income taxes and discontinued operations	492	483	934	922
Provision for income taxes	217	180	320	347
Earnings from continuing operations	275	303	614	575
Earnings from discontinued operations, net of tax	3	0	3	0
Net earnings	$278	$303	$617	$575
Basic earnings per common share:	'	'	'	'
Continuing operations	$0.80	$0.89	$1.80	$1.69
Discontinued operations	$0.01	$0	$0.01	$0
Net basic earnings per common share	$0.81	$0.89	$1.81	$1.69
Diluted earnings per common share:	'	'	'	'
Continuing operations	$0.79	$0.88	$1.78	$1.67
Discontinued operations	$0.01	$0	$0.01	$0
Net diluted earnings per common share	$0.80	$0.88	$1.79	$1.67
Weighted-average number of common shares outstanding:	'	'	'	'
Basic	342	340	341	340
Diluted	346	343	345	344
Cash dividends declared per common share	$0.30	$0.28	$0.61	$0.51

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Comprehensive Income (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Net earnings	$278	$303	$617	$575
Other comprehensive income:	'	'	'	'
Net change in foreign currency translation adjustments	4	11	28	36
Net unrealized gain on derivative instruments, net of tax	3	2	3	1
Total other comprehensive income, net of tax	7	13	31	37
Total comprehensive income	$285	$316	$648	$612

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Jun. 30, 2013
In Millions, unless otherwise specified
Current assets:	'	'
Cash and equivalents	$2,741	$1,901
Trade receivables, net	4,876	6,304
Inventories, net	8,478	8,373
Prepaid expenses and other	1,153	1,192
Total current assets	17,248	17,770
Property and equipment, net	1,407	1,489
Goodwill and other intangibles, net	5,556	5,574
Other assets	798	986
Total assets	25,009	25,819
Current liabilities:	'	'
Accounts payable	11,221	12,295
Current portion of long-term obligations and other short-term borrowings	255	168
Other accrued liabilities	1,886	2,127
Total current liabilities	13,362	14,590
Long-term obligations, less current portion	3,679	3,686
Deferred income taxes and other liabilities	1,379	1,568
Preferred shares, without par value:	'	'
Authorized-500 thousand shares, Issued-none	0	0
Common shares, without par value:	'	'
Authorized-755 million shares, Issued-364 million shares at December 31, 2013 and June 30, 2013	2,961	2,953
Retained earnings	4,446	4,038
Common shares in treasury, at cost: 21 million shares and 25 million shares at December 31, 2013 and June 30, 2013, respectively	-917	-1,084
Accumulated other comprehensive income	99	68
Total shareholders' equity	6,589	5,975
Total liabilities and shareholders' equity	$25,009	$25,819

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Jun. 30, 2013
In Millions, unless otherwise specified
Preferred shares, No Par Value	'	'
Preferred shares, Authorized	0.5	0.5
Preferred shares, Issued	0	0
Common shares, No Par Value	'	'
Common shares, Authorized	755	755
Common shares, Issued	364	364
Common shares in treasury	21	25

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (USD $)	6 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:	'	'
Net earnings	$617	$575
Earnings from discontinued operations, net of tax	-3	0
Earnings from continuing operations	614	575
Adjustments to reconcile earnings from continuing operations to net cash provided by operating activities:	'	'
Depreciation and amortization	234	176
Impairments and loss on disposal of assets	9	6
Share-based compensation	48	46
Provision for bad debts	29	9
Change in operating assets and liabilities, net of effects from acquisitions:	'	'
Decrease in trade receivables	1,420	228
Increase in inventories	-100	-536
Increase/(decrease) in accounts payable	-1,088	31
Other accrued liabilities and operating items, net	-178	-97
Net cash provided by operating activities	988	438
Cash flows from investing activities:	'	'
Acquisition of subsidiaries, net of cash acquired	-50	-126
Additions to property and equipment	-90	-62
Proceeds from maturities of held-to-maturity securities	0	71
Net cash used in investing activities	-140	-117
Cash flows from financing activities:	'	'
Net change in short-term borrowings	73	17
Reduction of long-term obligations	-1	-6
Net proceeds from issuance of common shares	139	26
Tax proceeds/(disbursements) from share-based compensation	39	-12
Dividends on common shares	-208	-165
Purchase of treasury shares	-50	-200
Net cash used in financing activities	-8	-340
Net increase/(decrease) in cash and equivalents	840	-19
Cash and equivalents at beginning of period	1,901	2,274
Cash and equivalents at end of period	$2,741	$2,255

Summary_of_Significant_Account

Summary of Significant Accounting Policies	6 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	Summary of Significant Accounting Policies
	Basis of Presentation
	Our condensed consolidated financial statements include the accounts of all majority-owned and controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. References to "we," "our" and similar pronouns in this Quarterly Report on Form 10-Q refer to Cardinal Health, Inc. and its majority-owned and controlled subsidiaries unless the context requires otherwise. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the effective date of the acquisition or up to the date of disposal, respectively.
	Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include all of the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. In addition, operating results presented for this fiscal 2014 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2014.
	These condensed consolidated financial statements are unaudited and are presented pursuant to the rules and regulations of the SEC. Accordingly, the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for the quarter ended December 31, 2013 (this "Form 10-Q") should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2013 (the "2013 Form 10-K"). In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.
	Walgreens Contract
	Our pharmaceutical distribution contract with Walgreen Co. ("Walgreens") expired on August 31, 2013. Sales to Walgreens generated approximately 20 percent of our consolidated revenue for fiscal 2013.
	CVS Contracts
	In December 2013, we announced the signing of an agreement with CVS Caremark Corporation (“CVS”) to form a U.S.-based generic sourcing entity (“Sourcing JV”). Both companies are contributing their sourcing and supply chain expertise to the 50/50 joint venture and are committing to source generic pharmaceuticals through it. The Sourcing JV, which we expect to be operational as soon as July 1, 2014, will have an initial term of 10 years. Under this arrangement, the Sourcing JV will negotiate generic supply contracts on behalf of both companies; however, it will not own products or hold inventory on behalf of either company. The arrangement includes a quarterly payment of $25 million over the term that we will pay to CVS. No physical assets will be contributed by either company to the Sourcing JV, and minimal funding will be provided to capitalize the entity. The venture is subject to the completion of final documentation and customary closing conditions.
	Also during the three months ended December 31, 2013, we entered into a three-year extension, through June 2019, of our existing pharmaceutical distribution contracts with CVS.
	Recent Financial Accounting Standards
	In February 2013, the Financial Accounting Standards Board ("FASB") issued amended accounting guidance related to reclassifications out of accumulated other comprehensive income ("AOCI"). An entity is required to present, either parenthetically on the face of the statement where net income is presented or in the notes, the significant amounts, by component, reclassified out of AOCI by the respective line items of net income and to report changes in its AOCI balances by component. We adopted this amended guidance on a prospective basis in the first quarter of fiscal 2014 and have elected to report reclassifications out of AOCI in Note 10 in this Form 10-Q. The adoption of this guidance did not impact our financial position or results of operations.
	In January 2013, the FASB issued updated guidance to limit the scope of the balance sheet offsetting disclosures to derivatives, repurchase agreements and securities lending transactions to the extent they are offset in the financial statements or subject to an enforceable master netting arrangement or similar arrangement. We adopted this amended guidance on a retrospective basis in the first quarter of fiscal 2014. The adoption of this guidance did not impact our financial position or results of operations. See Note 8 for additional information regarding fair value measurements.
	In July 2012, the FASB issued amended accounting guidance related to testing indefinite-lived intangible assets for impairment. Under this guidance, a company is no longer required to calculate the fair value of an indefinite-lived intangible asset unless the company determines, based on a qualitative assessment, that it is more likely than not that its estimated fair value is less than its carrying amount. We adopted this amended guidance in the first quarter of fiscal 2014. The adoption of this guidance did not impact our financial position or results of operations.

Acquisitions

Acquisitions	6 Months Ended
	Dec. 31, 2013
Business Combinations [Abstract]	'
Acquisitions	'
	Acquisitions
	While we have completed acquisitions during the six months ended December 31, 2013, the pro forma results of operations and the results of operations for acquisitions since the acquisition date have not been separately disclosed because the effects were not significant enough compared to the consolidated financial statements, individually or in the aggregate.
	AssuraMed
	On March 18, 2013, we completed the acquisition of AssuraMed, Inc. ("AssuraMed") for $2.07 billion, net of cash acquired, in an all-cash transaction. The acquisition of AssuraMed, a provider of medical supplies to homecare providers and patients in the home, expands our ability to serve this patient base. The assessment of fair value is preliminary and is based on information that was available at the time the condensed consolidated financial statements were prepared.
	The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the acquisition date for AssuraMed:
	(in millions)	Amount
	Identifiable intangible assets	$	627
	Cash and equivalents	25
	Trade receivables	117
	Inventories	69
	Prepaid expenses and other	90
	Property and equipment	40
	Accounts payable	(71		)
	Other accrued liabilities	(24		)
	Deferred income taxes and other liabilities	(180		)
	Total identifiable net assets acquired	693
	Goodwill	1,402
	Total net assets acquired	$	2,095

Restructuring_and_Employee_Sev

Restructuring and Employee Severance	6 Months Ended
	Dec. 31, 2013
Restructuring Charges [Abstract]	'
Restructuring and Employee Severance	'
	Restructuring and Employee Severance
	The following tables summarize restructuring and employee severance costs related to our restructuring activities:
		Three Months Ended December 31
	(in millions)	2013			2012
	Employee-related costs (1)	$	4		$	—
	Facility exit and other costs (2)	6			1
	Total restructuring and employee severance	$	10		$	1
		Six Months Ended December 31
	(in millions)	2013			2012
	Employee-related costs (1)	$	8		$	5
	Facility exit and other costs (2)	12			1
	Total restructuring and employee severance	$	20		$	6
	-1	Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated and duplicate payroll costs during transition periods.
	-2	Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.
	On January 30, 2013, we announced a restructuring plan within our Medical segment. Under this restructuring plan, among other things, we are moving production of procedure kits from our facility in Waukegan, Illinois to other facilities and selling property and consolidating office space in Waukegan, Illinois. We recognized restructuring costs of $6 million and $12 million related to this restructuring plan during the three and six months ended December 31, 2013, respectively, which primarily consisted of facility exit and other costs.
	We currently estimate the total costs associated with this restructuring plan to be approximately $77 million on a pre-tax basis, of which $51 million was recognized in fiscal 2013 and $20 million was recognized during the six months ended December 31, 2013, including the write-down of the property in Waukegan, Illinois as discussed in Note 4. The estimated $6 million remaining costs to be recognized through the end of fiscal 2014 consist of facility exit and other costs.
	The following table summarizes activity related to liabilities associated with restructuring and employee severance:
	(in millions)	Employee-			Facility Exit			Total
		Related Costs			and Other Costs
	Balance at June 30, 2013	$	55		$	2		$	57
	Additions	12			1			13
	Payments and other adjustments	(28		)	(2		)	(30		)
	Balance at December 31, 2013	$	39		$	1		$	40

Impairments_and_Loss_on_Dispos

Impairments and Loss on Disposal of Assets	6 Months Ended
	Dec. 31, 2013
Impairment or Disposal of Tangible Assets Disclosure [Abstract]	'
Impairments and loss on disposal of assets, Disclosure	'
	Impairments and Loss on Disposal of Assets
	In connection with our Medical segment restructuring plan discussed in Note 3, the property in Waukegan, Illinois met the criteria for classification as held for sale at December 31, 2013. As a result, during the three months ended December 31, 2013, we recognized an $8 million loss to write down this property to the estimated fair value, less costs to sell, of $24 million, which is included in prepaid expenses and other in the condensed consolidated balance sheets. The fair value was estimated using inputs such as broker listings and sales agreements and thus represents a Level 2 nonrecurring fair value measurement.

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	6 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Other Intangible Assets	'
	Goodwill and Other Intangible Assets
	Goodwill
	The following table summarizes the changes in the carrying amount of goodwill, by segment and in total:
	(in millions)	Pharmaceutical		Medical			Total
	Balance at June 30, 2013	$	2,094	$	2,507		$	4,601
	Goodwill acquired, net of purchase price adjustments	21		9			30
	Foreign currency translation adjustments and other	5		(1		)	4
	Balance at December 31, 2013	$	2,120	$	2,515		$	4,635
	Other Intangible Assets
	Other intangible assets are amortized over periods ranging from one to twenty years. The following tables summarize other intangible assets by class at:
		December 31, 2013
	(in millions)	Gross		Accumulated			Net
		Intangible		Amortization			Intangible
	Indefinite-life intangibles:
	Trademarks and other	$	11	$	—		$	11
	Total indefinite-life intangibles	11		—			11
	Definite-life intangibles:
	Customer relationships	1,011		311			700
	Trademarks, trade names and patents	213		60			153
	Non-compete agreements	15		11			4
	Other	108		55			53
	Total definite-life intangibles	1,347		437			910
	Total other intangible assets	$	1,358	$	437		$	921
		June 30, 2013
	(in millions)	Gross		Accumulated			Net
		Intangible		Amortization			Intangible
	Indefinite-life intangibles:
	Trademarks and other	$	11	$	—		$	11
	Total indefinite-life intangibles	11		—			11
	Definite-life intangibles:
	Customer relationships	982		230			752
	Trademarks, trade names and patents	209		49			160
	Non-compete agreements	15		10			5
	Other	101		56			45
	Total definite-life intangibles	1,307		345			962
	Total other intangible assets	$	1,318	$	345		$	973
	Total amortization of intangible assets was $46 million and $23 million for the three months ended December 31, 2013 and 2012, respectively, and $92 million and $44 million for the six months ended December 31, 2013 and 2012, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2014 through 2018 is as follows: $92 million, $157 million, $143 million, $131 million and $95 million.

Income_Taxes

Income Taxes	6 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	Fluctuations in our provision for income taxes as a percentage of pre-tax earnings (“effective tax rate”) are due to changes in international and U.S. state effective tax rates and discrete items.
	During the three months ended December 31, 2013, the effective tax rate of 44.1 percent was impacted by net unfavorable discrete items of $38 million, which increased the rate by 7.7 percentage points. The discrete items include the unfavorable impact of remeasurement of unrecognized tax benefits ($56 million) as a result of proposed assessments of additional tax.
	During the six months ended December 31, 2013, the effective tax rate of 34.2 percent was impacted by net favorable discrete items of $23 million, which reduced the rate by 2.4 percentage points. The discrete items include the favorable impact of the settlement of federal and state tax controversies ($67 million) and the unfavorable impact of remeasurement of unrecognized tax benefits ($56 million).
	During the three and six months ended December 31, 2012, the effective tax rate of 37.2 percent and 37.6 percent was impacted by net unfavorable discrete items of $2 million and $6 million, which increased the rate by 0.3 and 0.6 percentage points, respectively.
	We had $520 million and $650 million of unrecognized tax benefits at December 31, 2013 and June 30, 2013, respectively. The December 31, 2013 and June 30, 2013 balances include $339 million and $371 million, respectively, of unrecognized tax benefits that, if recognized, would have an impact on the effective tax rate. The remaining unrecognized tax benefits relate to tax positions for which ultimate deductibility is highly certain but for which there is uncertainty as to the timing of such deductibility. Recognition of these tax benefits would not affect our effective tax rate. We include the full amount of unrecognized tax benefits in deferred income taxes and other liabilities in the condensed consolidated balance sheets.
	We recognize accrued interest and penalties related to unrecognized tax benefits in the provision for income taxes. At December 31, 2013 and June 30, 2013 we had $140 million and $198 million, respectively, accrued for the payment of interest and penalties. These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets.
	It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, including proposed assessments of additional tax, possible settlement of audit issues, reassessment of existing unrecognized tax benefits or the expiration of applicable statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is a net decrease of approximately zero to $75 million, exclusive of penalties and interest.
	We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. We are generally subject to audit by taxing authorities for fiscal years 2003 through the current fiscal year.
	During the six months ended December 31, 2013, the IRS closed audits of fiscal years 2003 through 2005. The IRS is currently conducting audits of fiscal years 2006 through 2010, and our transfer pricing arrangements continue to be under consideration as part of these audits. While the IRS has made and could make proposed adjustments to our transfer pricing arrangements, or other matters, we are defending our reported tax positions, and have accounted for the unrecognized tax benefits associated with our tax positions.
	We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), under which CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $190 million and $186 million at December 31, 2013 and June 30, 2013, respectively, and is included in other assets in the condensed consolidated balance sheets.

Contingent_Liabilities_and_Lit

Contingent Liabilities and Litigation	6 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Contingent liabilities and litigation	'
	Contingent Liabilities and Litigation
	Legal Proceedings
	We become involved from time to time in disputes, litigation and regulatory matters incidental to our business, including governmental investigations and enforcement actions, personal injury claims, employment matters, commercial disputes, intellectual property matters, government contract compliance matters, disputes regarding environmental clean-up costs, claims in connection with acquisitions and divestitures, and other matters arising out of the normal conduct of our business. We intend to vigorously defend ourselves in such litigation.
	We may be named from time to time in qui tam actions, which are cases initiated by private parties purporting to act on behalf of federal or state governments that allege that false claims have been submitted or have been caused to be submitted for payment by the government. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in the matter. These actions may remain under seal while the government makes this determination.
	In addition, we occasionally may suspect that products we manufacture, market or distribute do not meet product specifications, published standards or regulatory requirements. In such circumstances, we investigate and take appropriate corrective action. Such actions can lead to product recalls, costs to repair or replace affected products, temporary interruptions in product sales and action by regulators.
	We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because litigation is inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.
	We are unable to estimate a range of reasonably possible loss for matters described below, since damages or fines have not been specified and the proceedings are in early stages with significant uncertainty as to factual issues. We do not believe, based on currently available information, that the outcomes of these matters will have a material adverse effect on our financial condition, though the outcomes could be material to our results of operations for a particular period.
	We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.
	We recognize estimated loss contingencies for litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges, net in our condensed consolidated statements of earnings.
	Lakeland, Florida Distribution Center DEA Investigation and Related Matters
	In February 2012, the U.S. Drug Enforcement Administration (the "DEA") issued an order to show cause and immediate suspension of our Lakeland, Florida distribution center's registration to distribute controlled substances, asserting that we failed to maintain required controls against the diversion of controlled substances. In May 2012, we entered into a settlement agreement with the DEA under which our Lakeland registration will remain suspended until May 2014 and the DEA confirmed that it was planning no further administrative actions at any of our other facilities based on conduct prior to the settlement. The settlement agreement did not foreclose the possibility of the U.S. Department of Justice (the “DOJ”) seeking civil fines for conduct covered by the settlement agreement. In that regard, we are providing information to and in discussions with the DEA and the DOJ.
	State of West Virginia vs. Cardinal Health, Inc.
	In June 2012, the West Virginia Attorney General filed, and in January 2014 amended, complaints against 13 pharmaceutical wholesale distributors, including us, in the Circuit Court of Boone County, West Virginia alleging, among other things, that the distributors failed to maintain effective controls to guard against diversion of controlled substances in West Virginia, failed to report suspicious orders of controlled substances in accordance with the West Virginia Uniform Controlled Substances Act and were negligent in distributing controlled substances to pharmacies that serve individuals who abuse controlled substances. In addition to injunctive and other equitable relief, the complaints seek monetary damages and the creation of a court-supervised fund, to be financed by the defendants in these actions, for a medical monitoring program focused on prescription drug abuse.
	DOJ Civil Investigative Demand
	In September 2012, we received a civil investigative demand from the DOJ under the federal False Claims Act. The demand required us to produce documents relating to the structure of discounts offered or provided to our customers. In October 2013, the DOJ informed us that it was closing its investigation.
	Federal False Claims Investigation
	The DOJ has requested information in connection with an investigation of possible violations of the federal False Claims Act with respect to our Medical segment’s administration of a prime vendor agreement with the federal government. We are cooperating with the DOJ in this matter.
	Antitrust Litigation Proceeds
	We recognized income resulting from settlements of class action antitrust claims in which we were a class member of $16 million and $12 million during the three months ended December 31, 2013 and 2012, respectively, and $16 million and $34 million during the six months ended December 31, 2013 and 2012, respectively.

Fair_Value_Measurements

Fair Value Measurements	6 Months Ended
	Dec. 31, 2013
Fair Value, Assets, Liabilities and Stockholders' Equity Measured on Recurring Basis [Abstract]	'
Fair Value Measurements	'
	Fair Value Measurements
	Fair value is defined as the price that would be received upon selling an asset or the price paid to transfer a liability on the measurement date. It focuses on the exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between willing market participants. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair values are as follows:
	Level 1 -	Observable prices in active markets for identical assets and liabilities.
	Level 2 -	Observable inputs other than quoted prices in active markets for identical assets and liabilities.
	Level 3 -	Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities.
	Recurring Fair Value Measurements
	The following tables present the fair values for those assets measured on a recurring basis at:
		December 31, 2013
	(in millions)	Level 1		Level 2		Level 3		Total
	Cash equivalents (1)	$	595	$	—	$	—	$	595
	Forward contracts (2)	—		17		—		17
	Other investments (3)	105		—		—		105
	Total	$	700	$	17	$	—	$	717
		June 30, 2013
	(in millions)	Level 1		Level 2		Level 3		Total
	Cash equivalents (1)	$	348	$	—	$	—	$	348
	Forward contracts (2)	—		12		—		12
	Other investments (3)	89		—		—		89
	Total	$	437	$	12	$	—	$	449
	-1	Cash equivalents are comprised of highly liquid investments purchased with a maturity of three months or less. The carrying value of these cash equivalents approximates fair value due to their short-term maturities.
	-2	The fair value of interest rate swaps, foreign currency contracts and commodity contracts is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in the condensed consolidated balance sheets.
	-3	The other investments balance includes investments in mutual funds, which are used to offset fluctuations in deferred compensation liabilities. These mutual funds primarily invest in the equity securities of companies with large market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.

Financial_Instruments_and_Othe

Financial Instruments and Other Financing Arrangements	6 Months Ended
	Dec. 31, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Financial Instruments and Other Financing Arrangements	'
	Financial Instruments and Other Financing Arrangements
	Financial Instruments
	We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. Our derivative and hedging programs are consistent with those described in our 2013 Form 10-K.
	During the six months ended December 31, 2013, we entered into pay-floating interest rate swaps with total notional amounts of $300 million. These swaps have been designated as fair value hedges of our fixed rate debt and are included in other assets in the condensed consolidated balance sheets at December 31, 2013.
	Fair Value of Financial Instruments
	The carrying amounts of cash and equivalents, trade receivables, net, accounts payable and other accrued liabilities at December 31, 2013 and June 30, 2013 approximate fair value due to their short-term maturities.
	The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:
	(in millions)	December 31,		June 30,
		2013		2013
	Estimated fair value	$	3,995	$	3,899
	Carrying amount	3,934		3,854
	The estimated fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement. See Note 8 for further information regarding fair value measurements.
	Other Financing Arrangements
	On October 15, 2013, we reduced our committed receivables sales facility program from $950 million to $700 million in light of the expiration of our pharmaceutical distribution contract with Walgreens. Our committed receivables sales facility program is available to us through Cardinal Health Funding, LLC ("CHF"), which was organized for the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated in accordance with GAAP, CHF is a separate legal entity from Cardinal Health and from our subsidiary that sells the receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors.

Shareholders_Equity

Shareholders' Equity	6 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Shareholders' Equity	'
	Shareholders' Equity
	During the six months ended December 31, 2013, we repurchased 1.0 million common shares having an aggregate cost of $50 million. The average price paid per common share was $51.65.
	During the six months ended December 31, 2012, we repurchased 4.9 million common shares having an aggregate cost of $200 million. The average price paid per common share was $40.63.
	We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes.
	Accumulated Other Comprehensive Income
	The following table summarizes the changes in the balance of AOCI by component and in total:
	(in millions)	Foreign		Unrealized			Accumulated Other
		Currency		Gain on			Comprehensive
		Translation		Derivatives,			Income
		Adjustments		net of tax
	Balance at June 30, 2013	$	54	$	14		$	68
	Other comprehensive income, net of tax before reclassifications	28		4			32
	Amounts reclassified to earnings	—		(1		)	(1		)
	Total other comprehensive income, net of tax	28		3			31
	Balance at December 31, 2013	$	82	$	17		$	99

Earnings_Per_Share

Earnings Per Share	6 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Earnings Per Share	'
	Earnings Per Share
	The following tables reconcile the number of common shares used to compute basic and diluted earnings per share:
		Three Months Ended December 31
	(in millions)	2013	2012
	Weighted-average common shares–basic	342	340
	Effect of dilutive securities:
	Employee stock options, restricted share units and performance share units	4	3
	Weighted-average common shares–diluted	346	343
		Six Months Ended December 31
	(in millions)	2013	2012
	Weighted-average common shares–basic	341	340
	Effect of dilutive securities:
	Employee stock options, restricted share units and performance share units	4	4
	Weighted-average common shares–diluted	345	344
	The potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive were zero and 12 million for the three months ended December 31, 2013 and 2012, respectively, and 2 million and 12 million for the six months ended December 31, 2013 and 2012, respectively.

Segment_Information

Segment Information	6 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Segment Information	'
	Segment Information
	Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates our performance combined with the nature of the individual business activities.
	The following tables present revenue for each reportable segment and reconciling items necessary to agree to amounts reported in the condensed consolidated statements of earnings:
		Three Months Ended December 31
	(in millions)	2013			2012
	Pharmaceutical (1)	$	19,443		$	22,747
	Medical	2,799			2,487
	Total segment revenue	22,242			25,234
	Corporate (2)	(2		)	(2		)
	Total revenue	$	22,240		$	25,232
		Six Months Ended December 31
	(in millions)	2013			2012
	Pharmaceutical (1)	$	41,256		$	46,244
	Medical	5,511			4,879
	Total segment revenue	46,767			51,123
	Corporate (2)	(4		)	(2		)
	Total revenue	$	46,763		$	51,121
	-1	The decrease in Pharmaceutical segment revenue is primarily due to the expiration of our pharmaceutical distribution contract with Walgreens.
	-2	Corporate revenue consists of the elimination of inter-segment revenue.
	We evaluate segment performance based upon segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&A") expenses. Segment SG&A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology and legal. Corporate expenses are allocated to the segments based upon headcount, level of benefit provided and ratable allocation. Other income, net, interest expense, net and provision for income taxes are not allocated to the segments.
	Restructuring and employee severance, amortization and other acquisition-related costs, impairments and loss on disposal of assets and litigation (recoveries)/charges, net are not allocated to the segments. In addition, certain investment and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. We encourage our segments and corporate functions to identify investment projects that will promote innovation and provide future returns. As approval decisions for such projects are dependent upon executive management, the expenses for such projects are often retained at Corporate. Investment spending within Corporate was $6 million and $7 million for the three months ended December 31, 2013 and 2012, respectively, and $10 million and $7 million for the six months ended December 31, 2013 and 2012, respectively.
	The following tables present segment profit by reportable segment and reconciling items necessary to agree to amounts reported in the condensed consolidated statements of earnings:
		Three Months Ended December 31
	(in millions)	2013			2012
	Pharmaceutical	$	482		$	441
	Medical	131			94
	Total segment profit	613			535
	Corporate	(94		)	(29		)
	Total operating earnings	$	519		$	506
		Six Months Ended December 31
	(in millions)	2013			2012
	Pharmaceutical	$	916		$	841
	Medical	238			168
	Total segment profit	1,154			1,009
	Corporate	(164		)	(46		)
	Total operating earnings	$	990		$	963
	The following table presents total assets for each reportable segment and reconciling items necessary to agree to amounts reported in the condensed consolidated balance sheets at the dates indicated below:
	(in millions)	December 31,			June 30,
		2013			2013
	Pharmaceutical (1)	$	14,985		$	16,258
	Medical	6,558			6,521
	Corporate	3,466			3,040
	Total assets	$	25,009		$	25,819
	-1	The decrease in Pharmaceutical segment assets is primarily due to the expiration of our pharmaceutical distribution contract with Walgreens.

ShareBased_Compensation

Share-Based Compensation	6 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments	'
	Share-Based Compensation
	Share-Based Compensation Plans
	We maintain stock incentive plans (collectively, the “Plans”) for the benefit of certain of our officers, directors and employees. The following tables provide total share-based compensation expense by type of award:
		Three Months Ended December 31
	(in millions)	2013			2012
	Restricted share unit expense	$	15		$	14
	Employee stock option expense	5			5
	Performance share unit expense	4			3
	Total share-based compensation	$	24		$	22
		Six Months Ended December 31
	(in millions)	2013			2012
	Restricted share unit expense	$	31		$	29
	Employee stock option expense	10			12
	Performance share unit expense	7			5
	Total share-based compensation	$	48		$	46
	The total tax benefit related to share-based compensation was $8 million for both the three months ended December 31, 2013 and 2012, respectively, and $17 million and $16 million for the six months ended December 31, 2013 and 2012, respectively.
	Stock Options
	Employee stock options granted under the Plans generally vest in equal annual installments over three years and are exercisable for periods ranging from seven to ten years from the grant date. All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date and, when exercised, are issued out of treasury shares.
	The following table summarizes all stock option transactions under the Plans:
	(in millions, except per share amounts)	Stock		Weighted-Average Exercise
		Options		Price per Common Share
	Outstanding at June 30, 2013	15		$	36.97
	Granted	2		51.77
	Exercised	(4	)	39.82
	Canceled and forfeited	—		—
	Outstanding at December 31, 2013	13		$	38.45
	Exercisable at December 31, 2013	8		$	34.31
	At December 31, 2013, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested stock options not yet recognized was $33 million, which is expected to be recognized over a weighted-average period of two years. The following table provides additional data related to stock option activity at:
	(in millions, except contractual lives)	December 31,			June 30,
		2013			2013
	Aggregate intrinsic value of outstanding options at period end	$	356		$	156
	Aggregate intrinsic value of exercisable options at period end	$	262		$	113
	Weighted-average remaining contractual life of outstanding options (in years)	5			4
	Weighted-average remaining contractual life of exercisable options (in years)	3			3
	Stock options are granted to our officers and certain employees. The fair values were estimated on the grant date using a lattice valuation model. We believe the lattice model provides reasonable estimates because it has the ability to take into account individual exercise patterns based on changes in our stock price and other variables, and it provides for a range of input assumptions.
	Restricted Share Units
	Restricted share units granted under the Plans generally vest in equal annual installments over three years. The fair value is determined by the grant date market price of our common shares. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.
	The following table summarizes all transactions related to restricted share units under the Plans:
	(in millions, except per share amounts)	Restricted Share Units		Weighted-Average Grant Date Fair Value per Share
	Nonvested at June 30, 2013	3		$	38.74
	Granted	1		51.96
	Vested	(1	)	37.41
	Canceled and forfeited	—		—
	Nonvested at December 31, 2013	3		$	45.2
	At December 31, 2013, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $102 million, which is expected to be recognized over a weighted-average period of two years.
	Performance Share Units
	Performance share units vest over a three-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 200 percent of the target award amount. The fair value of performance share units is determined by the grant date market price of our common shares. The compensation expense associated with nonvested performance share units is dependent on our periodic assessment of the probability of the targets being achieved and our estimate of the number of shares that will ultimately be issued. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.
	During the six months ended December 31, 2013, 274 thousand performance share units were granted at target at a weighted-average fair value per share of $51.49. Also during the six months ended December 31, 2013, 157 thousand performance share units with an initial two-year performance period and a weighted-average grant date fair value per share of $41.60 vested based on achievement of 143 percent of the target performance goal. At December 31, 2013, there were 868 thousand nonvested performance share units with a weighted-average grant date fair value per share of $44.39.
	At December 31, 2013, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $21 million, which is expected to be recognized over a weighted-average period of two years.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policy)	6 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Basis of Presentation, Policy	'
	Basis of Presentation
	Our condensed consolidated financial statements include the accounts of all majority-owned and controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. References to "we," "our" and similar pronouns in this Quarterly Report on Form 10-Q refer to Cardinal Health, Inc. and its majority-owned and controlled subsidiaries unless the context requires otherwise. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the effective date of the acquisition or up to the date of disposal, respectively.
	Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include all of the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. In addition, operating results presented for this fiscal 2014 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2014.
	These condensed consolidated financial statements are unaudited and are presented pursuant to the rules and regulations of the SEC. Accordingly, the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for the quarter ended December 31, 2013 (this "Form 10-Q") should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2013 (the "2013 Form 10-K"). In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.
Recent Financial Accounting Standards, Policy	'
	Recent Financial Accounting Standards
	In February 2013, the Financial Accounting Standards Board ("FASB") issued amended accounting guidance related to reclassifications out of accumulated other comprehensive income ("AOCI"). An entity is required to present, either parenthetically on the face of the statement where net income is presented or in the notes, the significant amounts, by component, reclassified out of AOCI by the respective line items of net income and to report changes in its AOCI balances by component. We adopted this amended guidance on a prospective basis in the first quarter of fiscal 2014 and have elected to report reclassifications out of AOCI in Note 10 in this Form 10-Q. The adoption of this guidance did not impact our financial position or results of operations.
	In January 2013, the FASB issued updated guidance to limit the scope of the balance sheet offsetting disclosures to derivatives, repurchase agreements and securities lending transactions to the extent they are offset in the financial statements or subject to an enforceable master netting arrangement or similar arrangement. We adopted this amended guidance on a retrospective basis in the first quarter of fiscal 2014. The adoption of this guidance did not impact our financial position or results of operations. See Note 8 for additional information regarding fair value measurements.
	In July 2012, the FASB issued amended accounting guidance related to testing indefinite-lived intangible assets for impairment. Under this guidance, a company is no longer required to calculate the fair value of an indefinite-lived intangible asset unless the company determines, based on a qualitative assessment, that it is more likely than not that its estimated fair value is less than its carrying amount. We adopted this amended guidance in the first quarter of fiscal 2014. The adoption of this guidance did not impact our financial position or results of operations.

Acquisitions_Tables

Acquisitions (Tables)	6 Months Ended
	Dec. 31, 2013
Business Combinations [Abstract]	'
Schedule of estimated fair values of the assets acquired and liabilities assumed	'
	The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the acquisition date for AssuraMed:
	(in millions)	Amount
	Identifiable intangible assets	$	627
	Cash and equivalents	25
	Trade receivables	117
	Inventories	69
	Prepaid expenses and other	90
	Property and equipment	40
	Accounts payable	(71		)
	Other accrued liabilities	(24		)
	Deferred income taxes and other liabilities	(180		)
	Total identifiable net assets acquired	693
	Goodwill	1,402
	Total net assets acquired	$	2,095

Restructuring_and_Employee_Sev1

Restructuring and Employee Severance (Tables)	6 Months Ended
	Dec. 31, 2013
Restructuring Charges [Abstract]	'
Summary of restructuring and employee severance relating to restructuring activity	'
	The following tables summarize restructuring and employee severance costs related to our restructuring activities:
		Three Months Ended December 31
	(in millions)	2013			2012
	Employee-related costs (1)	$	4		$	—
	Facility exit and other costs (2)	6			1
	Total restructuring and employee severance	$	10		$	1
		Six Months Ended December 31
	(in millions)	2013			2012
	Employee-related costs (1)	$	8		$	5
	Facility exit and other costs (2)	12			1
	Total restructuring and employee severance	$	20		$	6
	-1	Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated and duplicate payroll costs during transition periods.
	-2	Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.
Schedule of activity related to liabilities associated with restructuring and employee severance	'
	The following table summarizes activity related to liabilities associated with restructuring and employee severance:
	(in millions)	Employee-			Facility Exit			Total
		Related Costs			and Other Costs
	Balance at June 30, 2013	$	55		$	2		$	57
	Additions	12			1			13
	Payments and other adjustments	(28		)	(2		)	(30		)
	Balance at December 31, 2013	$	39		$	1		$	40

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets (Tables)	6 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Goodwill by Reportable Segment	'
	The following table summarizes the changes in the carrying amount of goodwill, by segment and in total:
	(in millions)	Pharmaceutical		Medical			Total
	Balance at June 30, 2013	$	2,094	$	2,507		$	4,601
	Goodwill acquired, net of purchase price adjustments	21		9			30
	Foreign currency translation adjustments and other	5		(1		)	4
	Balance at December 31, 2013	$	2,120	$	2,515		$	4,635
Schedule of Intangible Assets	'
	The following tables summarize other intangible assets by class at:
		December 31, 2013
	(in millions)	Gross		Accumulated			Net
		Intangible		Amortization			Intangible
	Indefinite-life intangibles:
	Trademarks and other	$	11	$	—		$	11
	Total indefinite-life intangibles	11		—			11
	Definite-life intangibles:
	Customer relationships	1,011		311			700
	Trademarks, trade names and patents	213		60			153
	Non-compete agreements	15		11			4
	Other	108		55			53
	Total definite-life intangibles	1,347		437			910
	Total other intangible assets	$	1,358	$	437		$	921
		June 30, 2013
	(in millions)	Gross		Accumulated			Net
		Intangible		Amortization			Intangible
	Indefinite-life intangibles:
	Trademarks and other	$	11	$	—		$	11
	Total indefinite-life intangibles	11		—			11
	Definite-life intangibles:
	Customer relationships	982		230			752
	Trademarks, trade names and patents	209		49			160
	Non-compete agreements	15		10			5
	Other	101		56			45
	Total definite-life intangibles	1,307		345			962
	Total other intangible assets	$	1,318	$	345		$	973

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	6 Months Ended
	Dec. 31, 2013
Fair Value, Assets, Liabilities and Stockholders' Equity Measured on Recurring Basis [Abstract]	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'
	The following tables present the fair values for those assets measured on a recurring basis at:
		December 31, 2013
	(in millions)	Level 1		Level 2		Level 3		Total
	Cash equivalents (1)	$	595	$	—	$	—	$	595
	Forward contracts (2)	—		17		—		17
	Other investments (3)	105		—		—		105
	Total	$	700	$	17	$	—	$	717
		June 30, 2013
	(in millions)	Level 1		Level 2		Level 3		Total
	Cash equivalents (1)	$	348	$	—	$	—	$	348
	Forward contracts (2)	—		12		—		12
	Other investments (3)	89		—		—		89
	Total	$	437	$	12	$	—	$	449
	-1	Cash equivalents are comprised of highly liquid investments purchased with a maturity of three months or less. The carrying value of these cash equivalents approximates fair value due to their short-term maturities.
	-2	The fair value of interest rate swaps, foreign currency contracts and commodity contracts is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in the condensed consolidated balance sheets.
	-3	The other investments balance includes investments in mutual funds, which are used to offset fluctuations in deferred compensation liabilities. These mutual funds primarily invest in the equity securities of companies with large market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.

Financial_Instruments_and_Othe1

Financial Instruments and Other Financing Arrangements (Tables)	6 Months Ended
	Dec. 31, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Summary of the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts	'
	The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:
	(in millions)	December 31,		June 30,
		2013		2013
	Estimated fair value	$	3,995	$	3,899
	Carrying amount	3,934		3,854

Shareholders_Equity_Tables

Shareholders' Equity (Tables)	6 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Schedule of the changes in the balance of AOCI by component and in total	'
	The following table summarizes the changes in the balance of AOCI by component and in total:
	(in millions)	Foreign		Unrealized			Accumulated Other
		Currency		Gain on			Comprehensive
		Translation		Derivatives,			Income
		Adjustments		net of tax
	Balance at June 30, 2013	$	54	$	14		$	68
	Other comprehensive income, net of tax before reclassifications	28		4			32
	Amounts reclassified to earnings	—		(1		)	(1		)
	Total other comprehensive income, net of tax	28		3			31
	Balance at December 31, 2013	$	82	$	17		$	99

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	6 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Reconciliation of common shares used to compute basic and diluted earnings per share	'
	The following tables reconcile the number of common shares used to compute basic and diluted earnings per share:
		Three Months Ended December 31
	(in millions)	2013	2012
	Weighted-average common shares–basic	342	340
	Effect of dilutive securities:
	Employee stock options, restricted share units and performance share units	4	3
	Weighted-average common shares–diluted	346	343
		Six Months Ended December 31
	(in millions)	2013	2012
	Weighted-average common shares–basic	341	340
	Effect of dilutive securities:
	Employee stock options, restricted share units and performance share units	4	4
	Weighted-average common shares–diluted	345	344

Segment_Information_Tables

Segment Information (Tables)	6 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Revenue by Reportable Segment	'
	The following tables present revenue for each reportable segment and reconciling items necessary to agree to amounts reported in the condensed consolidated statements of earnings:
		Three Months Ended December 31
	(in millions)	2013			2012
	Pharmaceutical (1)	$	19,443		$	22,747
	Medical	2,799			2,487
	Total segment revenue	22,242			25,234
	Corporate (2)	(2		)	(2		)
	Total revenue	$	22,240		$	25,232
		Six Months Ended December 31
	(in millions)	2013			2012
	Pharmaceutical (1)	$	41,256		$	46,244
	Medical	5,511			4,879
	Total segment revenue	46,767			51,123
	Corporate (2)	(4		)	(2		)
	Total revenue	$	46,763		$	51,121
	-1	The decrease in Pharmaceutical segment revenue is primarily due to the expiration of our pharmaceutical distribution contract with Walgreens.
	-2	Corporate revenue consists of the elimination of inter-segment revenue.
Segment Profit by Reportable Segment	'
	The following tables present segment profit by reportable segment and reconciling items necessary to agree to amounts reported in the condensed consolidated statements of earnings:
		Three Months Ended December 31
	(in millions)	2013			2012
	Pharmaceutical	$	482		$	441
	Medical	131			94
	Total segment profit	613			535
	Corporate	(94		)	(29		)
	Total operating earnings	$	519		$	506
		Six Months Ended December 31
	(in millions)	2013			2012
	Pharmaceutical	$	916		$	841
	Medical	238			168
	Total segment profit	1,154			1,009
	Corporate	(164		)	(46		)
	Total operating earnings	$	990		$	963
Assets by Reportable Segments	'
	The following table presents total assets for each reportable segment and reconciling items necessary to agree to amounts reported in the condensed consolidated balance sheets at the dates indicated below:
	(in millions)	December 31,			June 30,
		2013			2013
	Pharmaceutical (1)	$	14,985		$	16,258
	Medical	6,558			6,521
	Corporate	3,466			3,040
	Total assets	$	25,009		$	25,819
	-1	The decrease in Pharmaceutical segment assets is primarily due to the expiration of our pharmaceutical distribution contract with Walgreens.

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	6 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of total share-based compensation expense by type of award	'
	The following tables provide total share-based compensation expense by type of award:
		Three Months Ended December 31
	(in millions)	2013			2012
	Restricted share unit expense	$	15		$	14
	Employee stock option expense	5			5
	Performance share unit expense	4			3
	Total share-based compensation	$	24		$	22
		Six Months Ended December 31
	(in millions)	2013			2012
	Restricted share unit expense	$	31		$	29
	Employee stock option expense	10			12
	Performance share unit expense	7			5
	Total share-based compensation	$	48		$	46
Schedule of all stock option transactions under the Plans	'
	The following table summarizes all stock option transactions under the Plans:
	(in millions, except per share amounts)	Stock		Weighted-Average Exercise
		Options		Price per Common Share
	Outstanding at June 30, 2013	15		$	36.97
	Granted	2		51.77
	Exercised	(4	)	39.82
	Canceled and forfeited	—		—
	Outstanding at December 31, 2013	13		$	38.45
	Exercisable at December 31, 2013	8		$	34.31
Schedule of additional data related to stock option activity	'
	The following table provides additional data related to stock option activity at:
	(in millions, except contractual lives)	December 31,			June 30,
		2013			2013
	Aggregate intrinsic value of outstanding options at period end	$	356		$	156
	Aggregate intrinsic value of exercisable options at period end	$	262		$	113
	Weighted-average remaining contractual life of outstanding options (in years)	5			4
	Weighted-average remaining contractual life of exercisable options (in years)	3			3
Schedule of all transactions related to restricted share units under the Plans	'
	The following table summarizes all transactions related to restricted share units under the Plans:
	(in millions, except per share amounts)	Restricted Share Units		Weighted-Average Grant Date Fair Value per Share
	Nonvested at June 30, 2013	3		$	38.74
	Granted	1		51.96
	Vested	(1	)	37.41
	Canceled and forfeited	—		—
	Nonvested at December 31, 2013	3		$	45.2

Summary_of_Significant_Account2

Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Narrative) (Details) (USD $)	3 Months Ended	6 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2013	Jun. 30, 2013
	Cvs Caremark Corporation Member	Pharmaceutical	Pharmaceutical
		Walgreens Co Member	Walgreens Co Member
Concentration Risk [Line Items]	'	'	'
Contract expiration date	30-Jun-19	31-Aug-13	'
Revenue, Major Customer, Percentage	'	'	20.00%
Expected JV Operational Date	1-Jul-14	'	'
Term of Agreement	'10 years	'	'
Quarterly joint venture payment	$25	'	'
Number of Years of Contract	'3 years	'	'

Acquisitions_Narrative_Details

Acquisitions (Narrative) (Details) (USD $)	6 Months Ended		0 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Mar. 18, 2013
			AssuraMed
Business Acquisition	'	'	'
Business Acquisition, Effective Date of Acquisition	'	'	18-Mar-13
Payments to Acquire Businesses, Net of Cash Acquired	$50	$126	$2,070

Acquisitions_Schedule_of_Estim

Acquisitions (Schedule of Estimated Fair Values of the Assets Acquired and Liabilities Assumed) (Details) (USD $)	Dec. 31, 2013	Jun. 30, 2013
In Millions, unless otherwise specified
Business Acquisition	'	'
Goodwill	$4,635	$4,601
AssuraMed	'	'
Business Acquisition	'	'
Identifiable intangible assets	627	'
Cash and equivalents	25	'
Trade receivables	117	'
Inventories	69	'
Prepaid expenses and other	90	'
Property and equipment	40	'
Accounts payable	-71	'
Other accrued liabilities	-24	'
Deferred income taxes and other liabilities	-180	'
Total identifiable net assets acquired	693	'
Goodwill	1,402	'
Total net assets acquired	$2,095	'

Restructuring_and_Employee_Sev2

Restructuring and Employee Severance (Narrative) (Details) (USD $)	3 Months Ended		6 Months Ended		3 Months Ended	6 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2013
					Fiscal 2013 Medical Restructuring	Fiscal 2013 Medical Restructuring	Fiscal 2013 Medical Restructuring	Fiscal 2013 Medical Restructuring
Restructuring Cost and Reserve	'	'	'	'	'	'	'	'
Restructuring and Related Activities, Initiation Date	'	'	'	'	'	'	'	30-Jan-13
Restructuring and employee severance	$10	$1	$20	$6	$6	'	$12	'
Restructuring and Related Cost, Expected Cost	'	'	'	'	'	6	77	'
Restructuring and Related Cost, Cost Incurred to Date	'	'	'	'	'	'	$20	$51

Restructuring_and_Employee_Sev3

Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) (USD $)	3 Months Ended				6 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2013		Dec. 31, 2012
Restructuring Cost and Reserve	'		'		'		'
Employee-related costs	$4	[1]	$0	[1]	$8	[1]	$5	[1]
Facility exit and other costs	6	[2]	1	[2]	12	[2]	1	[2]
Restructuring and employee severance	10		1		20		6
Fiscal 2013 Medical Restructuring	'		'		'		'
Restructuring Cost and Reserve	'		'		'		'
Restructuring and employee severance	$6		'		$12		'
[1]	Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated and duplicate payroll costs during transition periods.
[2]	Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.

Restructuring_and_Employee_Sev4

Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013
Employee-Related Costs	'
Restructuring Reserve [Roll Forward]	'
Balance at June 30, 2013	$55
Additions to Restructuring Reserve	12
Restructuring Reserve, Period Increase (Decrease)	-28
Balance at December 31, 2013	39
Facility Exit and Other Costs	'
Restructuring Reserve [Roll Forward]	'
Balance at June 30, 2013	2
Additions to Restructuring Reserve	1
Restructuring Reserve, Period Increase (Decrease)	-2
Balance at December 31, 2013	1
Total	'
Restructuring Reserve [Roll Forward]	'
Balance at June 30, 2013	57
Additions to Restructuring Reserve	13
Restructuring Reserve, Period Increase (Decrease)	-30
Balance at December 31, 2013	$40

Impairments_and_Loss_on_Dispos1

Impairments and Loss on Disposal of Assets (Narrative) (Details) (Medical, Waukegan, Illinois Property, USD $)	3 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013
Long Lived Assets Held-for-sale [Line Items]	'
Impairment of Long-Lived Assets to be Disposed of	$8
Fair Value, Inputs, Level 2	'
Long Lived Assets Held-for-sale [Line Items]	'
Assets Held-for-sale, Long Lived	$24

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets (Narrative) (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Goodwill and Intangible Assets	'	'	'	'
Amortization of Intangible Assets	$46	$23	$92	$44
Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year	92	'	92	'
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	157	'	157	'
Finite-Lived Intangible Assets, Amortization Expense, Year Two	143	'	143	'
Finite-Lived Intangible Assets, Amortization Expense, Year Three	131	'	131	'
Finite-Lived Intangible Assets, Amortization Expense, Year Four	$95	'	$95	'
Minimum	'	'	'	'
Goodwill and Intangible Assets	'	'	'	'
Finite-Lived Intangible Asset, Useful Life	'	'	'1 year	'
Maximum	'	'	'	'
Goodwill and Intangible Assets	'	'	'	'
Finite-Lived Intangible Asset, Useful Life	'	'	'20 years	'

Goodwill_and_Other_Intangible_3

Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013
Goodwill [Roll Forward]	'
Balance at June 30, 2013	$4,601
Goodwill acquired, net of purchase price adjustments	30
Foreign currency translation adjustments and other	4
Balance at December 31, 2013	4,635
Pharmaceutical	'
Goodwill [Roll Forward]	'
Balance at June 30, 2013	2,094
Goodwill acquired, net of purchase price adjustments	21
Foreign currency translation adjustments and other	5
Balance at December 31, 2013	2,120
Medical	'
Goodwill [Roll Forward]	'
Balance at June 30, 2013	2,507
Goodwill acquired, net of purchase price adjustments	9
Foreign currency translation adjustments and other	-1
Balance at December 31, 2013	$2,515

Goodwill_and_Other_Intangible_4

Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) (USD $)	Dec. 31, 2013	Jun. 30, 2013
In Millions, unless otherwise specified
Total Intangibles, Gross	$1,358	$1,318
Total Intangibles, Accumulated Amortization	437	345
Intangible Assets, Net (Excluding Goodwill)	921	973
Indefinite-life intangibles:	'	'
Indefinite-Lived Intangible Assets, Gross	11	11
Indefinite-Lived Intangible Assets, Accumulated Amortization	0	0
Indefinite-Lived Intangible Assets (Excluding Goodwill)	11	11
Definite-life intangibles:	'	'
Finite-Lived Intangible Assets, Gross	1,347	1,307
Finite-Lived Intangible Assets, Accumulated Amortization	437	345
Finite-Lived Intangible Assets, Net	910	962
Customer relationships	'	'
Definite-life intangibles:	'	'
Finite-Lived Intangible Assets, Gross	1,011	982
Finite-Lived Intangible Assets, Accumulated Amortization	311	230
Finite-Lived Intangible Assets, Net	700	752
Trademarks, trade names and patents	'	'
Definite-life intangibles:	'	'
Finite-Lived Intangible Assets, Gross	213	209
Finite-Lived Intangible Assets, Accumulated Amortization	60	49
Finite-Lived Intangible Assets, Net	153	160
Non-compete agreements	'	'
Definite-life intangibles:	'	'
Finite-Lived Intangible Assets, Gross	15	15
Finite-Lived Intangible Assets, Accumulated Amortization	11	10
Finite-Lived Intangible Assets, Net	4	5
Other	'	'
Definite-life intangibles:	'	'
Finite-Lived Intangible Assets, Gross	108	101
Finite-Lived Intangible Assets, Accumulated Amortization	55	56
Finite-Lived Intangible Assets, Net	53	45
Trademarks and other	'	'
Indefinite-life intangibles:	'	'
Indefinite-Lived Intangible Assets, Gross	11	11
Indefinite-Lived Intangible Assets, Accumulated Amortization	0	0
Indefinite-Lived Intangible Assets (Excluding Goodwill)	$11	$11

Income_Taxes_Narrative_Details

Income Taxes (Narrative) (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Jun. 30, 2013
Income Taxes	'	'	'	'	'
Effective Income Tax Rate, Continuing Operations	44.10%	37.20%	34.20%	37.60%	'
Net Unfavorable/(Favorable) Discrete Items, Amount	$38	$2	($23)	$6	'
Net Unfavorable/(Favorable) Discrete Items, Percentage	7.70%	0.30%	-2.40%	0.60%	'
(Favorable) impact of settlement of federal and state tax controversies	'	'	-67	'	'
Unrecognized Tax Benefits, Period Increase (Decrease)	56	'	56	'	'
Unrecognized tax benefits	520	'	520	'	650
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	339	'	339	'	371
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued	140	'	140	'	198
Significant Increase/(Decrease) in Unrecognized Tax Benefits is Reasonably Possible, Estimated Range of Change, Lower Bound	0	'	0	'	'
Significant Increase/(Decrease) in Unrecognized Tax Benefits is Reasonably Possible, Estimated Range of Change, Upper Bound	75	'	75	'	'
Amount CareFusion is liable under tax matters agreement in the event amount must be paid to the taxing authority	$190	'	$190	'	$186
Minimum	'	'	'	'	'
Income Taxes	'	'	'	'	'
Tax years open for examination	'	'	'2003	'	'
Tax years under examination	'	'	'2006	'	'
Tax years closed that were under examination	'	'	'2003	'	'
Maximum	'	'	'	'	'
Income Taxes	'	'	'	'	'
Tax years open for examination	'	'	'2014	'	'
Tax years under examination	'	'	'2010	'	'
Tax years closed that were under examination	'	'	'2005	'	'

Contingent_Liabilities_and_Lit1

Contingent Liabilities and Litigation (Narrative) (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Gain (Loss) Related to Litigation Settlement [Abstract]	'	'	'	'
Litigation Settlement, Gross	$16	$12	$16	$34
State of West Virginia vs Cardinal Health, Inc	'	'	'	'
Loss Contingencies [Line Items]	'	'	'	'
Loss Contingency, Number of Defendants	'	'	13	'

Fair_Value_Measurements_Fair_V

Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details) (USD $)	Dec. 31, 2013		Jun. 30, 2013
In Millions, unless otherwise specified
Fair Value, Balance Sheet Grouping, Financial Statement Captions	'		'
Cash equivalents	$595	[1]	$348	[1]
Forward contracts	17	[2]	12	[2]
Other investments	105	[3]	89	[3]
Total	717		449
Fair Value, Inputs, Level 1	'		'
Fair Value, Balance Sheet Grouping, Financial Statement Captions	'		'
Cash equivalents	595	[1]	348	[1]
Forward contracts	0	[2]	0	[2]
Other investments	105	[3]	89	[3]
Total	700		437
Fair Value, Inputs, Level 2	'		'
Fair Value, Balance Sheet Grouping, Financial Statement Captions	'		'
Cash equivalents	0	[1]	0	[1]
Forward contracts	17	[2]	12	[2]
Other investments	0	[3]	0	[3]
Total	17		12
Fair Value, Inputs, Level 3	'		'
Fair Value, Balance Sheet Grouping, Financial Statement Captions	'		'
Cash equivalents	0	[1]	0	[1]
Forward contracts	0	[2]	0	[2]
Other investments	0	[3]	0	[3]
Total	$0		$0
[1]	Cash equivalents are comprised of highly liquid investments purchased with a maturity of three months or less. The carrying value of these cash equivalents approximates fair value due to their short-term maturities.
[2]	The fair value of interest rate swaps, foreign currency contracts and commodity contracts is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in the condensed consolidated balance sheets.
[3]	The other investments balance includes investments in mutual funds, which are used to offset fluctuations in deferred compensation liabilities. These mutual funds primarily invest in the equity securities of companies with large market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.

Financial_Instruments_and_Othe2

Financial Instruments and Other Financing Arrangements (Narrative) (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013
Committed Receivables Sales Facility Program	'	'
Derivative [Line Items]	'	'
Line of Credit Facility, Effective Date of Reduction	15-Oct-13	'
Line of Credit Facility, Maximum Borrowing Capacity	$700	$950
Pay-floating interest rate swap	'	'
Derivative [Line Items]	'	'
Derivative, Notional Amount	$300	'

Financial_Instruments_and_Othe3

Financial Instruments and Other Financing Arrangements (Summary of Estimated Fair Value of Our Long-Term Obligations and Other Short-Term Borrowings) (Details) (USD $)	Dec. 31, 2013	Jun. 30, 2013
In Millions, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Carrying amount	$3,934	$3,854
Fair Value, Inputs, Level 2	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Estimated fair value	$3,995	$3,899

Shareholders_Equity_Narrative_

Shareholders' Equity (Narrative) (Details) (Treasury Shares, USD $)	6 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Treasury Shares	'	'
Treasury shares acquired (using Cost Method), Shares	1	4.9
Treasury shares acquired (using Cost Method), Value	$50	$200
Treasury Stock Acquired, Average Cost Per Share	$51.65	$40.63

Shareholders_Equity_Schedule_o

Shareholders' Equity (Schedule of the changes in the balance in AOCI by component and in total) (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Rollforward]	'	'	'	'
Balance at June 30, 2013	'	'	$68	'
Other comprehensive income, before reclassifications	'	'	32	'
Amounts reclassified to earnings	'	'	-1	'
Other Comprehensive Income, Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent	4	11	28	36
Other Comprehensive Income, Derivatives Qualifying as Hedges, Net of Tax	3	2	3	1
Total other comprehensive income, net of tax	7	13	31	37
Balance at December 31, 2013	99	'	99	'
Foreign Currency Translation Adjustments	'	'	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Rollforward]	'	'	'	'
Balance at June 30, 2013	'	'	54	'
Other comprehensive income, before reclassifications	'	'	28	'
Amounts reclassified to earnings	'	'	0	'
Other Comprehensive Income, Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent	'	'	28	'
Balance at December 31, 2013	82	'	82	'
Unrealized Gain/(Loss) on Derivatives, net of tax	'	'	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Rollforward]	'	'	'	'
Balance at June 30, 2013	'	'	14	'
Other comprehensive income, before reclassifications	'	'	4	'
Amounts reclassified to earnings	'	'	-1	'
Other Comprehensive Income, Derivatives Qualifying as Hedges, Net of Tax	'	'	3	'
Balance at December 31, 2013	$17	'	$17	'

Earnings_Per_Share_Narrative_D

Earnings Per Share (Narrative) (Details)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Earnings Per Share [Abstract]	'	'	'	'
Potentially dilutive employee stock options, restricted share units and performance share units that were anitdilutive	0	12	2	12

Earnings_Per_Share_Reconciliat

Earnings Per Share (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Earnings Per Share [Abstract]	'	'	'	'
Weighted-average common shares-basic	342	340	341	340
Effect of dilutive securities:	'	'	'	'
Employee stock options, restricted share units and performance share units	4	3	4	4
Weighted-average common shares-diluted	346	343	345	344

Segment_Information_Narrative_

Segment Information (Narrative) (Details) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Jun. 30, 2013
			Segment		Segment
Segment Reporting [Abstract]	'	'	'	'	'
Number of Operating Segments	'	'	2	'	2
Number of Reportable Segments	'	'	2	'	2
Project Costs On Investment And Other Spending	$6	$7	$10	$7	'

Segment_Information_Revenue_by

Segment Information (Revenue by Reportable Segment) (Details) (USD $)	3 Months Ended				6 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2013		Dec. 31, 2012
Segment Reporting Information	'		'		'		'
Revenue	$22,240		$25,232		$46,763		$51,121
Pharmaceutical	'		'		'		'
Segment Reporting Information	'		'		'		'
Revenue	19,443	[1]	22,747		41,256	[1]	46,244
Medical	'		'		'		'
Segment Reporting Information	'		'		'		'
Revenue	2,799		2,487		5,511		4,879
Reportable Segments	'		'		'		'
Segment Reporting Information	'		'		'		'
Revenue	22,242		25,234		46,767		51,123
Corporate	'		'		'		'
Segment Reporting Information	'		'		'		'
Revenue	($2)	[2]	($2)	[2]	($4)	[2]	($2)	[2]
[1]	The decrease in Pharmaceutical segment revenue is primarily due to the expiration of our pharmaceutical distribution contract with Walgreens.
[2]	Corporate revenue consists of the elimination of inter-segment revenue.

Segment_Information_Segment_Pr

Segment Information (Segment Profit by Reportable Segment) (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'	'	'
Operating earnings	$519	$506	$990	$963
Pharmaceutical	'	'	'	'
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'	'	'
Operating earnings	482	441	916	841
Medical	'	'	'	'
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'	'	'
Operating earnings	131	94	238	168
Reportable Segments	'	'	'	'
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'	'	'
Operating earnings	613	535	1,154	1,009
Corporate	'	'	'	'
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'	'	'
Operating earnings	($94)	($29)	($164)	($46)

Segment_Information_Segment_In

Segment Information Segment Information (Assets by Reportable Segment) (Details) (USD $)	Dec. 31, 2013		Jun. 30, 2013
In Millions, unless otherwise specified
Segment Reporting, Asset Reconciling Item	'		'
Assets	$25,009		$25,819
Pharmaceutical	'		'
Segment Reporting, Asset Reconciling Item	'		'
Assets	14,985	[1]	16,258
Medical	'		'
Segment Reporting, Asset Reconciling Item	'		'
Assets	6,558		6,521
Corporate	'		'
Segment Reporting, Asset Reconciling Item	'		'
Assets	$3,466		$3,040
[1]	The decrease in Pharmaceutical segment assets is primarily due to the expiration of our pharmaceutical distribution contract with Walgreens.

ShareBased_Compensation_Narrat

Share-Based Compensation (Narrative) (Details) (USD $)

3 Months Ended

6 Months Ended

6 Months Ended

In Millions, except Share data in Thousands, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Stock Options

Stock Options

Stock Options

Restricted Share Units

Restricted Share Units

Performance Share Units

Performance Share Units

Performance Share Units

Minimum

Maximum

Minimum

Maximum

Share-based Compensation Arrangement by Share-based Payment Award

'

'

'

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Tax Benefit from Compensation Expense

$8

$8

$17

$16

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period, in years

'

'

'

'

'3 years

'

'

'3 years

'

'

'2 years

'3 years

Exercisable period of plans, in years

'

'

'

'

'

'7 years

'10 years

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized

'

'

'

'

$33

'

'

$102

'

$21

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition

'

'

'

'

'2 years

'

'

'2 years

'

'2 years

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage

'

'

'

'

'

'

'

'

'

143.00%

0.00%

200.00%

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period

'

'

'

'

'

'

'

1,000

'

274

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value

'

'

'

'

'

'

'

$51.96

'

$51.49

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period

'

'

'

'

'

'

'

1,000

'

157

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value

'

'

'

'

'

'

'

$37.41

'

$41.60

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested

'

'

'

'

'

'

'

3,000

3,000

868

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value

'

'

'

'

'

'

'

$45.20

$38.74

$44.39

'

'

ShareBased_Compensation_Schedu

Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Share-based compensation expense	$24	$22	$48	$46
Restricted Share Units	'	'	'	'
Share-based compensation expense	15	14	31	29
Stock Options	'	'	'	'
Share-based compensation expense	5	5	10	12
Performance Share Units	'	'	'	'
Share-based compensation expense	$4	$3	$7	$5

ShareBased_Compensation_Schedu1

Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details) (USD $)	6 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'
Stock Options Outstanding at June 30, 2013	15
Stock Options Outstanding, Granted	2
Stock Options Outstanding, Exercised	-4
Stock Options Outstanding, Canceled and forfeited	0
Stock Options Outstanding at December 31, 2013	13
Stock Options Outstanding, Exercisable at December 31, 2013	8
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted-Average Exercise Price [Roll Forward]	'
Weighted-Average Exercise Price Per Common Share, Outstanding at June 30, 2013	$36.97
Weighted-Average Exercise Price Per Common Share, Granted	$51.77
Weighted-Average Exercise Price Per Common Share, Exercised	$39.82
Weighted-Average Exercise Price Per Common Share, Canceled and forfeited	$0
Weighted-Average Exercise Price Per Common Share, Outstanding at December 31, 2013	$38.45
Weighted-Average Exercise Price Per Common Share, Exercisable at December 31, 2013	$34.31

ShareBased_Compensation_Schedu2

Share-Based Compensation (Schedule of Additional Data Related to Stock Option Activity) (Details) (Stock Options, USD $)	6 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Jun. 30, 2013
Stock Options	'	'
Aggregate intrinsic value of outstanding options at period end, Stock Options	$356	$156
Aggregate intrinsic value of exercisable options at period end, Stock Options	$262	$113
Weighted-average remaining contractual life of outstanding options (in years)	'5 years	'4 years
Weighted-average remaining contractual life of exercisable options (in years)	'3 years	'3 years

ShareBased_Compensation_Schedu3

Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) (Restricted Share Units, USD $)	6 Months Ended
	Dec. 31, 2013
Restricted Share Units	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]	'
Restricted Share Units Nonvested at June 30, 2013	3,000,000
Restricted Share Units, Granted	1,000,000
Restricted Share Units, Vested	-1,000,000
Restricted Share Units, Canceled and forfeited	0
Restricted Share Units Nonvested at December 31, 2013	3,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted-Average Grant Date Fair Value [Roll Forward]	'
Weighted-Average Grant Date Fair Value Per Share, Nonvested at June 30, 2013	$38.74
Weighted-Average Grant Date Fair Value Per Share, Granted	$51.96
Weighted-Average Grant Date Fair Value Per Share, Vested	$37.41
Weighted-Average Grant Date Fair Value Per Share, Canceled and forfeited	$0
Weighted-Average Grant Date Fair Value Per Share, Nonvested at December 31, 2013	$45.20